First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Cancer immunology, immunotherapy : CII（2023）
关键词
Pembrolizumab,Non-small cell lung cancer,Advanced stage,Brain metastases,Real-world study
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要